Abstract 2182
Background
Immune checkpoint inhibitors mediated by PD-1 and PD-L1 are promising treatments for various tumors. The PD-L1 expression in tumor cells was found to be correlated with the likelihood of a response to PD-1- or PD-L1-targeted therapy in non-small cell lung cancer (NSCLC). For PD-L1 immunohistochemistry (IHC), 22C3 pharmDx is the only companion diagnostic assay that can identify NSCLC patients suitable for pembrolizumab treatment. Specimens are scored and divided into 3 categories (<1%, 1-49%, ≥50%) based on the tumor proportion score (TPS). The PD-L1 prevalence in NSCLC patients screened for the KEYNOTE-024 trial was 31% with TPS <1%, 39% with TPS 1-49%, and 30% with TPS ≥50%. While specimens used for the IHC 22C3 assay are recommended to be formalin-fixed for 12-72 h, the specimens were fixed in 10% neutral-buffered formalin for less than 6 h in our institution. Thus, we retrospectively assessed the PD-L1 prevalence in NSCLC patients to determine whether the PD-L1 TPS differs according to the duration of formalin fixation.
Methods
We screened consecutive NSCLC patients who underwent tumor biopsy by bronchoscopy between January 2017 and June 2018 at National Hospital Organization Fukuokahigashi Medical Center. In the present study, we only included 70 patients whose tumors were formalin-fixed for less than 6 h and whose PD-L1 expression had been evaluated by IHC with antibodies to human PD-L1 (22C3 pharmDx).
Results
The PD-L1 prevalence in patients with NSCLC in our hospital was 26 (37%) with TPS<1%, 23 (33%) with TPS 1-49%, and 21 (30%) with TPS ≥50%, suggesting that small biopsy samples obtained by bronchoscopy that were formalin-fixed for <6 h are suitable for PD-L1 IHC. We also performed analyzed in 35 surgically-resected NSCLC specimens that had been formalin-fixed for 1-7 days by PD-L1 IHC. The PD-L1 prevalence was 20 (57%) for TPS < 1%, 9 (26%) for TPS 1-49%, and 6 (17%) for TPS ≥50%.
Conclusions
The PD-L1 prevalence in specimens with short-duration formalin fixation was consistent with the results of the KEYNOTE-024 trial. We will present our conclusion regarding these results, including the characteristics of patients and the PD-L1 prevalence in specimens fixed for 12-72 h in our institution, from July 2018 onward.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Hospital Organization Fukuokahigashi Medical Center.
Funding
JSPS KAKENHI JP18K15927.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract